EGR-1 activation by EGF inhibits MMP-9 expression and lymphoma growth

被引:32
作者
Bouchard, Frederic [1 ]
Belanger, Simon D. [1 ]
Biron-Pain, Katherine [1 ]
St-Pierre, Yves [1 ]
机构
[1] Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, Laval, PQ H7V 1B7, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
TRANSCRIPTION FACTOR EGR-1; TUMORS IN-VIVO; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; MYELOID DIFFERENTIATION; TNF-ALPHA; CANCER; MICROENVIRONMENT; MATRIX-METALLOPROTEINASE-9;
D O I
10.1182/blood-2009-12-257030
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Progression of hematologic malignancies is strongly dependent on bidirectional interactions between tumor cells and stromal cells. Expression of members of the matrix metalloproteinase (MMP) family by stromal cells is a central event during these interactions. However, although several studies have focused on the mechanisms responsible for induction of MMP in stromal cells, the signals that negatively regulate their secretion of in these cells remain largely unknown. Here, we provide evidence that MMP-9 production by stromal cells is suppressed through activation of early growth response protein 1 (EGR-1), thereby inhibiting the growth of thymic lymphoma. We found that EGR-1 expression is induced in stromal cells after contact with lymphoma cells via epidermal growth factor (EGF). Moreover, development of thymic lymphoma was inhibited when induced by lymphoma cells overexpressing EGF compared with control lymphoma cells. Using transgenic mice containing MMP-9 promoter-driven luciferase transgene in its genome, we further demonstrated that EGF/EGR-1 repressed transcriptional activation of the MMP-9 gene by stromal cells. De novo expression of EGR-1 alone by gene transfer or exposure to recombinant human EGF also inhibited MMP-9 expression. Taken together, these results indicate that EGR-1 could be a source of novel targets for therapeutic intervention in lymphoid tumors in which MMP-9 plays a critical role. (Blood. 2010;116(5):759-766)
引用
收藏
页码:759 / 766
页数:8
相关论文
共 62 条
[1]
Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment [J].
Acuff, HB ;
Carter, KJ ;
Fingleton, B ;
Gorden, DL ;
Matrisian, LM .
CANCER RESEARCH, 2006, 66 (01) :259-266
[2]
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis [J].
Amano, Hideki ;
Ito, Yoshiya ;
Suzuki, Tastunori ;
Kato, Shintaro ;
Matsui, Yoshio ;
Ogawa, Fumihiro ;
Murata, Takahiko ;
Sugimoto, Yukihiko ;
Senior, Robert ;
Kitasato, Hidero ;
Hayashi, Izumi ;
Satoh, Yukitoshi ;
Narumiya, Shuh ;
Majima, Masataka .
CANCER SCIENCE, 2009, 100 (12) :2318-2324
[3]
Aoudjit F, 1998, J IMMUNOL, V160, P2967
[4]
Aoudjit F, 1997, INT J CANCER, V71, P71, DOI 10.1002/(SICI)1097-0215(19970328)71:1<71::AID-IJC13>3.3.CO
[5]
2-O
[6]
The metastatic characteristics of murine lymphoma cell lines in vivo are manifested after target organ invasion [J].
Aoudjit, F ;
Potworowski, EF ;
St-Pierre, Y .
BLOOD, 1998, 91 (02) :623-629
[7]
Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo [J].
Baron, V ;
De Gregorio, G ;
Krones-Herzig, A ;
Virolle, T ;
Calogero, A ;
Urcis, R ;
Mercola, D .
ONCOGENE, 2003, 22 (27) :4194-4204
[8]
CALORI G, 2001, J GLOBAL ENV ENG, V7, P1
[9]
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment [J].
Chantrain, CF ;
Shimada, H ;
Jodele, S ;
Groshen, S ;
Ye, W ;
Shalinsky, DR ;
Werb, Z ;
Coussens, LM ;
DeClerck, YA .
CANCER RESEARCH, 2004, 64 (05) :1675-1686
[10]
Inhibition of the RelA(p65) NF-κB subunit by Egr-1 [J].
Chapman, NR ;
Perkins, ND .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (07) :4719-4725